GRI Bio Narrows Q1 Loss, Reports Positive Phase 2a IPF Trial Data & Cash Runway to Q2 2027
summarizeSummary
GRI Bio, Inc. reported significantly improved Q1 2026 financial results, with net loss narrowing to $2 million and diluted EPS improving to $(1.61). Crucially for this clinical-stage biotech, the company announced positive Phase 2a trial results for GRI-0621 in idiopathic pulmonary fibrosis (IPF), meeting the primary safety endpoint and showing supportive efficacy signals. Furthermore, the company confirmed it has raised capital through ATM and public offerings, extending its cash runway into Q2 2027. This news is highly material for a micro-cap company that previously faced a going concern warning and Nasdaq listing challenges, as it addresses critical financial stability concerns and provides a significant clinical catalyst. Investors will now watch for further progress on the planned Phase 2b trial and continued financial management.
At the time of this announcement, GRI was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $2.10 to $80.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.